Astra-Oxford Vaccine Shows Two Different Efficacy Rates

The transcript discusses the AstraZeneca vaccine's efficacy, highlighting differences in patient cohorts and the need for further analysis to understand these variations. It also examines the timing of vaccine data releases and their market impact, questioning the rationale behind such decisions. The conversation shifts to future vaccine developments, including the anticipated results from NovaVax's phase three trial, and the importance of understanding vaccine efficacy in preventing infection.

What critical piece of information is sought regarding the efficacy of the vaccine?

What is the expected timeline for the phase three trial results for Nova VAX?